Cantitate/Preț
Produs

Organic Syntheses, Volume 94: Organic Syntheses

Autor Margaret Faul
en Limba Engleză Hardback – 13 sep 2018
The current volume continues the tradition of the Organic Syntheses series, providing carefully checked and edited experimental procedures that describe important synthetic methods, transformations, reagents, and synthetic building blocks or intermediates with demonstrated utility in organic synthesis. These significant and interesting procedures should prove worthwhile to many synthetic chemists working in increasingly diverse areas. A trusted guide for professionals in organic and medicinal chemistry in academia, government, and industries, including pharmaceuticals, fine chemicals, agrochemicals, and biotechnological products.
Citește tot Restrânge

Din seria Organic Syntheses

Preț: 80531 lei

Nou

Puncte Express: 1208

Preț estimativ în valută:
15417 16741$ 12965£

Carte disponibilă

Livrare economică 26 noiembrie-10 decembrie
Livrare express 09-15 noiembrie pentru 5388 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781119511946
ISBN-10: 1119511941
Pagini: 448
Dimensiuni: 158 x 236 x 27 mm
Greutate: 0.88 kg
Ediția:Volume 94
Editura: Wiley
Seria Organic Syntheses

Locul publicării:Hoboken, United States

Public țintă

Students and Professionals in Organic Chemistry and Medicinal Chemistry in academia, government, and industries including pharmaceuticals, fine chemicals, agrochemicals, and biotech.

Notă biografică

Margaret M. Faul received her B.Sc. and M.Sc degrees from University College Dublin, Ireland. She then moved to the US where she received her Ph.D. degree in synthetic organic chemistry from Harvard University with Professor David A. Evans. In 1993 Margaret joined the Chemical Process group at Eli Lilly and Company, and in 2003 she moved to Amgen where she is currently the Executive Director in the Process Development organization. At Amgen, Margaret is responsible for the commercial process development and process characterization of all molecules in both the synthetic and biologic Amgen portfolio.